Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
1. A formulation comprising:
a plurality of substrates comprising a portion of an effective dose of methylphenidate or a pharmaceutically acceptable salt coated with a hydrophobic material in an amount to obtain a weight gain from about 2% to about 25%, the hydrophobic material comprising a first acrylic polymer,
an enteric coating applied over said hydrophobic material in an amount sufficient to delay the release of said portion until after said formulation passes through the stomach, wherein said enteric coating is derived from an aqueous dispersion comprising a second acrylic polymer,
the formulation further comprising the remaining portion of said dose in an immediate release form,
wherein the formulation provides a biphasic release profile, a mean maximum plasma concentration of said methylphenidate at about 2 hours and methylphenidate plasma concentrations below effective plasma concentration at about 8 hour to about 12 hours after an oral administration.
2. The formulation of claim 1 , wherein the formulation provides an in-vitro dissolution as follows:
Time
% Methylphenidate
(hours)
Dissolved
0.25
0-45%
1
5-50%
4
40-90%
8
NLT 60%
12
NLT 80%.
3. The formulation of claim 1 , wherein said remaining portion is included as an immediate release powder, an immediate release granulate, immediate release matrix spheroids, immediate release beads, or an immediate release layer over said enteric coating.
4. The formulation of claim 1 , which provides a peak plasma concentration of the methylphenidate which is from about 1.0 to about 2.0 times the plasma concentration of the methylphenidate provided by the formulation at about 9 hours after said administration.
5. The formulation of claim 1 , wherein methylphenidate plasma concentration falls below effective plasma concentration at about 12 hours after said administration.
6. The formulation of claim 1 which is a capsule.
7. A formulation comprising:
a plurality of substrates comprising a portion of an effective dose of methylphenidate or a pharmaceutically acceptable salt coated with a hydrophobic material in an amount to obtain a weight gain from about 2% to about 25%, the hydrophobic material comprising an alkylcellulose, a first acrylic polymer or mixtures thereof,
an enteric coating applied over said hydrophobic material in an amount sufficient to delay the release of said portion until after said formulation passes through the stomach, wherein said enteric coating is derived from an aqueous dispersion comprising a second acrylic polymer, the formulation further comprising the remaining portion of said dose in an immediate release form,
wherein the formulation provides a mean AUC 0-t of 48493.80 pg×h/ml, a mean AUC 0-inf of 51213.86 pg×h/ml, a mean C max of 4410.25 pg/ml, a mean T max of 3.27 hours, a mean K el of 0.1672 h −1 , and a mean T 1/2 el of 4.32 hours, based on a fasting administration of a formulation comprising 20 mg of said methylphenidate.
8. The formulation of claim 7 , wherein the formulation provides an in-vitro dissolution as follows:
Time
% Methylphenidate
(hours)
Dissolved
0.25
0-45%
1
5-50%
4
40-90%
8
NLT 60%
12
NLT 80%.
9. The formulation of claim 7 , wherein said remaining portion is included as an immediate release powder, an immediate release granulate, immediate release matrix spheroids, immediate release beads, or an immediate release layer over said enteric coating.
10. The formulation of claim 7 , which provides a peak plasma concentration of the methylphenidate which is from about 1.0 to about 2.0 times the plasma concentration of the methylphenidate provided by the formulation at about 9 hours after said administration.
11. The formulation of claim 7 , wherein methylphenidate plasma concentration falls below effective plasma concentration at about 8 to about 12 hours after said administration.
12. The formulation of claim 7 , which is a capsule.